Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Sutro Biopharma, Inc.NASDAQ: STRO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.56M fell 71.8% year over year, behind the -58.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at -18.9% a year.

Context

  • Stock-based compensation amounted to 13.7% of revenue in FY2025, down 26.1 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -71.8% toward the trailing-twelve-month pace of -58.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.56M-5.6% QoQ
Last fiscal yearDec 2025
$14.01M-43.3% YoY
LTMMar 2026
$10.03M-58.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.8%——
1 year-43.3%——
3-year CAGR-18.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
14.01M USD
Year-over-year change
-43.3%
4-year CAGR
-11.9%

Stock-Based Compensation vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -58.5% is the 7th highest of 8, against a peer median of -28.8%.
  • Stock-based compensation amounts to 10.1% of revenue for STRO, versus a peer median of 3295.4%.
STRO Competitors
Stock-Based Compensation for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$21.58M USD-41.5%+5.1%—
STROSutro Biopharma, Inc.LTM Mar 2026$10.03M USD-58.5%-18.9%10.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$8.91M USD-28.8%-19.0%19.8%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$7.81M USD-26.4%+28.7%—
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$6.36M USD-16.6%+1.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$3.73M USD-44.6%+54.6%5821.9%
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
KLRSKalaris Therapeutics IncLTM Mar 2026$638K USD———
Peer median (excluding STRO) —-28.8%+3.9%3295.4%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Depreciation & Amortization4.84M5.69M6.82M7.22M7.32M
Deferred Income Tax7.24M0000
Stock-Based Compensation23.24M26.3M24.91M24.69M14.01M
Change in Working Capital(17.62M)104.41M(34.38M)8.9M(50.4M)
Accounts Receivables(6.9M)5.34M(28.96M)27.46M4.64M
Inventory(4.55M)0000
Accounts Payables6.43M(1.23M)4.81M706K(2.47M)
Other Working Capital(12.61M)100.29M(10.23M)(19.27M)(52.57M)
Other Non-Cash Items6.16M(13.65M)(2.17M)(4.88M)42.92M
Operating Cash Flow(81.68M)3.55M(111.62M)(191.54M)(177.23M)
Capital Expenditures(15.32M)(7.86M)(4.32M)(3.1M)(1.7M)
Acquisitions (Net)028.74M000
Purchases of Investments(248.73M)(216.67M)(460.3M)(461.52M)(264.95M)
Sales of Investments166.73M189.5M460.69M683.13M311.66M
Other Investing Activities9K(28.73M)000
Investing Cash Flow(97.32M)(35.02M)(3.92M)218.51M45.01M
Debt Repayment0(9.38M)(12.5M)(4.08M)0
Common Stock Issued056.27M11.97M96.53M376K
Common Stock Repurchased(7K)0000
Dividends Paid00000
Other Financing Activities4.25M1.42M138.08M1.61M(332K)
Financing Cash Flow3.26M48.31M137.55M94.05M44K
Effect of Forex Changes00000
Net Change in Cash(175.74M)16.84M22.01M121.02M(132.17M)
Free Cash Flow(97M)(4.31M)(115.93M)(194.64M)(178.93M)

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.